China Approves World's First Commercial Brain-Computer Interface for Spinal Cord Injury Treatment
核心洞察
China's National Medical Products Administration (搜索) approved the world's first invasive brain (搜索)-computer interface medical device for commercial use, marking a global breakthrough in the field.
The device, developed by Neuracle Medical Technology (搜索), assists quadriplegic patients with spinal cord injuries in achieving hand grasping functions through a minimally invasive epidural implant.
With over 3.7 million spinal cord injury (搜索) patients in China and 15 million globally, this approval addresses a significant unmet medical need for a condition considered refractory by the medical community.
China has achieved a world-first milestone by approving the first invasive brain (搜索)-computer interface (BCI) medical device for commercial use, marking a breakthrough in treating spinal cord injuries. The National Medical Products Administration (搜索) (NMPA) approved the device developed by Neuracle Medical Technology (搜索) (also referenced as Borui Kang Medical Technology (搜索)), making it the first such technology to move beyond clinical trials to broad patient access globally.
Revolutionary Technology for Paralyzed Patients
The approved device, officially named the Implantable Brain-Computer Interface Hand Movement Compensation System (搜索), is specifically designed for quadriplegic patients with spinal cord injuries. The system consists of a coin-sized wireless implant that sits on the surface of the brain (搜索)'s outer membrane and controls a robotic glove, enabling patients to achieve hand grasping functions.
The device employs an internationally pioneering minimally invasive implantation technique on the epidural layer (搜索) of the brain (搜索), combined with wireless power supply communication technology. Crucially, the system acquires brain electrical signals without contacting brain tissue or damaging nerve cells, offering what developers describe as long-term stability and reliability with minimal trauma.
Addressing a Massive Unmet Medical Need
The approval addresses a significant global health challenge. According to Deputy Director of the Department of Neurosurgery at Huashan Hospital, Fudan University, China currently has over 3.7 million cumulative patients with spinal cord injuries, with an additional 90,000 new cases occurring annually. Globally, there are 15 million cumulative patients, with over 70% being under the age of 50.
Spinal cord injury (搜索) is considered a refractory condition in the medical community, with the majority of patients suffering from high-level paralysis (搜索) and remaining bedridden for extended periods. Particularly challenging are cases where the illness exceeds one year, as rehabilitation of neurological function becomes extremely difficult. These patients are commonly referred to as 'silent patients' in clinical practice.
Global Context and Competition
While brain (搜索) implants have been used in clinical trials for decades, this marks the first time such a device has received approval for broad commercial use. In the United States, companies like Neuralink (搜索), Synchron (搜索), and Paradromics (搜索) are developing similar technologies but remain in experimental phases. Neuralink, founded by Elon Musk, has enrolled 21 participants in its trial as of January 2026, but no BCI devices have been approved for commercial use in the U.S.
The BrainGate (搜索) consortium, one of the leading research groups since the early 2000s, has developed devices that enable participants with locked-in syndrome (搜索) to control computer mice and type on virtual keyboards, but these remain research tools rather than commercial products.
Regulatory Framework and Safety Standards
Peng Liang, Deputy Minister of the First Evaluation Department of the Center for Medical Device Evaluation under the NMPA, emphasized that the most critical feature of brain (搜索)-computer interface medical devices is their ability to read and analyze brain signals in real time and interact with external devices to fulfill medical purposes. The NMPA explicitly stressed that brain-computer interface medical devices differ from ordinary brain-computer interface products and must possess specific core elements intended for clinical treatment.
The device falls under Class III medical devices, representing the highest regulatory category, and underwent strict approval processes by pharmaceutical regulatory authorities. Officials described this as a 'globally new' product, specifically referring to completely new medical devices that have not been marketed anywhere in the world.
Market Response and Investment Climate
Following the announcement, related concept stocks in the Hong Kong stock market immediately gained momentum. Shares of Sanbo Brain (搜索) Science, Innovation Medical, and Nanjing Panda all surged by more than 10%, significantly boosting market sentiment.
The approval reflects China's strategic prioritization of brain (搜索)-computer interfaces, which are listed as one of six future strategic industries in the latest five-year plan. The government has committed to accelerating regulatory approval processes and is researching medical insurance reimbursement guidelines in advance of product launches, with goals to nurture globally leading brain-computer interface enterprises by the end of this decade.
This supportive policy environment has attracted significant capital investment. Shanghai Jieti Medical Technology (搜索), one of the earliest companies in China to initiate clinical trials for brain (搜索) chips, completed a RMB 500 million financing round led by Alibaba Group. Additionally, Chengdu Gotak Technology (搜索) announced completion of a RMB 150 million seed funding round.
The approval represents a breakthrough from 0 to 1 in the global development of invasive brain (搜索)-computer interface medical devices, filling a clinical gap both internationally and domestically while establishing China as a leader in this emerging field.